Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955943 | PMC |
| http://dx.doi.org/10.1016/j.tibs.2021.03.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Challenges and strategies in the soluble expression of CTA1-(S14P5)4-DD and CTA1-(S21P2)4-DD fusion proteins as candidates for COVID-19 intranasal vaccines.
PLoS One
December 2024
Research Organization for Health, National Research and Innovation (BRIN), Cibinong, Indonesia.
Developing intranasal vaccines against pandemics and devastating airborne infectious diseases is imperative. The superiority of intranasal vaccines over injectable systemic vaccines is evident, but developing effective intranasal vaccines presents significant challenges. Fusing a protein antigen with the catalytic domain of cholera toxin (CTA1) and the two-domain D of staphylococcal protein A (DD) has significant potential for intranasal vaccines.
View Article and Find Full Text PDFDual-Mechanism mRNA Delivery via Fluorinated-Sorbitol Polyplexes: Enhancing Cellular Uptake and Endosomal Escape for COVID-19 Vaccination.
Adv Healthc Mater
December 2024
Department of Biomedical Sciences, Biomedical Sciences Graduate Program (BMSGP), Chonnam National University Medical School, 322 Seoyang-ro, Hwasun, 58128, Republic of Korea.
Advancements in mRNA delivery nanoparticles have significantly improved the potential for treating challenging diseases. Due to the inherent immunogenicity and rapid degradation of mRNA, specialized nanoparticles are required for efficient intracellular uptake, endosomal escape, and protection from lysosomal degradation. Although current methods enable transgene expression but achieving a balance between efficiency and toxicity remains challenging.
View Article and Find Full Text PDF"They need to speak a language everyone can understand": Accessibility of COVID-19 vaccine information for Canadian adults with intellectual and developmental disabilities.
Vaccine
December 2024
Azrieli Adult Neurodevelopmental Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. Electronic address:
Accessible vaccine information is one vital component of effective vaccination programs, however, there is limited research that explores how people with disabilities engage with public health messaging. This study aimed to understand how adults with intellectual and developmental disabilities (IDD) and their caregivers navigated Canada's public health communications regarding COVID-19 vaccines. A national survey on the accessibility of vaccine information was conducted in the spring and summer of 2022.
View Article and Find Full Text PDFImmunogenicity and safety of SARS-CoV-2 recombinant protein vaccine (CHO cell) LYB001 as a heterologous booster following two- or three-dose inactivated COVID-19 vaccine in adults aged ≥18 years: interim results of a randomized, active-controlled, double-blinded, phase 3 trial.
Expert Rev Vaccines
December 2024
Guangzhou Patronus Biotech Co, Ltd, Guangzhou, China.
Background: LYB001 is a recombinant protein COVID-19 vaccine displaying a receptor-binding domain (RBD) in a highly immunogenic array on virus-like particles (VLPs). This study assessed the immunogenicity and safety of LYB001 as a booster.
Research Design And Methods: In this randomized, active-controlled, double-blinded, phase 3 trial, participants aged ≥18 years received a booster with LYB001 or ZF2001 (Recombinant COVID-19 Vaccine).
Real-world effectiveness and causal mediation study of BNT162b2 on long COVID risks in children and adolescents.
EClinicalMedicine
January 2025
Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Background: The impact of pre-infection vaccination on the risk of long COVID remains unclear in the pediatric population. We aim to assess the effectiveness of BNT162b2 on long COVID risks with various strains of the SARS-CoV-2 virus in children and adolescents, using comparative effectiveness methods. We further explore if such pre-infection vaccination can mitigate the risk of long COVID beyond its established protective benefits against SARS-CoV-2 infection using causal mediation analysis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!